A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today. Responding to a recent opinion piece in the New England Journal of Medicine, Nickels said, “The 340B program is more important now than ever before as the prices of prescription drugs continue to skyrocket. Instead of trying to make changes to a program with a strong track record of increasing access to care for patients in vulnerable communities, policymakers should consider other solutions, such as requiring greater transparency on drug pricing and charity policies by drug companies, increased competition in the generic industry or other reasonable proposals.” For more on the 340B program, visit www.aha.org/protect340B.

Related News Articles

Perspective
Two weeks ago, I wrote about the
Headline
The U.S. Court of Appeals for the District of Columbia Circuit reversed the voiding of a rule that included Medicare and private insurance payments when…
Headline
The Health Resources and Services Administration yesterday awarded 80 rural consortia $1 million each to help prevent, treat and support recovery for patients…
Headline
The AHA today voiced support for the Improving Seniors’ Timely Access to Care Act (H.R. 3107), bipartisan legislation that would establish requirements for the…
Headline
Medicare will cover nationally Chimeric Antigen Receptor T-cell therapies approved by the Food and Drug Administration to treat certain cancers, as well as off…
Headline
Offering a government insurance program reimbursing at Medicare rates as a public option on the health insurance exchanges could place as many as 55% of rural…